A recent study analyzed the long-term efficacy and safety profile of anti–tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus and rheumatoid arthritis (RA) in the same patient.
A study published in December 2017 analyzed the long-term efficacy and safety profile of anti—tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient. Authors of the study note that, to date, there have been no previous studies regarding the use of anti-TNF agents in the treatment of rhupus.
Researchers conducted an open-label, single-center pilot study comprising 15 patients diagnosed with rhupus from 2003 to 2012 with a disease activity score for 28 joints (DAS28) over 3.2. Patients were monitored at 3, 6, 12, 24, and 60 months using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and DAS28.
Of the 15 patients included in the study, 12 were treated with etanercept for a median duration of 62.5 months, and 3 patients were given adalimumab for a median of 36 months. At baseline, median DAS28 and SLEDAI were 5.94 and 6, respectively, in the 2 groups. After 3 months of treatment, DAS28 and SLEDAI decreased to 3.7 and 4, respectively. The authors found that the tolerability and safety profile of the anti-TNF agents were acceptable, with a severe infection rate of 3 per 100 patient years, and with no lupus flares occurring during the follow-up.
The researchers concluded that anti-TNF treatment resulted in an improvement of articular symptoms with a significant decrease of DAS28 score. The SLEDAI score decreased after 3 months of therapy, and these numbers were sustained during the follow-up. Notably, this score also declined without taking into account the arthritis component of the SLEDAI, which the authors suggest could mean that anti-TNF agents could improve the non-articular features of lupus.
This small-scale study suggested that anti-TNF treatment has a “favorable efficacy, a decrease in the median dose of glucocorticoids, and an acceptable tolerance profile in patients with rhupus with refractive arthritis,” said the researchers.
Reference
Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of anti-tumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open. 2017;3:e000555. doi: 10.1136/rmdopen-2017-000555.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.